200 related articles for article (PubMed ID: 26275051)
1. Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway.
Čokić VP; Mossuz P; Han J; Socoro N; Beleslin-Čokić BB; Mitrović O; Subotički T; Diklić M; Leković D; Gotić M; Puri RK; Noguchi CT; Schechter AN
PLoS One; 2015; 10(8):e0135463. PubMed ID: 26275051
[TBL] [Abstract][Full Text] [Related]
2. TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms.
Kovačić M; Mitrović-Ajtić O; Beleslin-Čokić B; Djikić D; Subotički T; Diklić M; Leković D; Gotić M; Mossuz P; Čokić VP
Cell Oncol (Dordr); 2018 Oct; 41(5):541-553. PubMed ID: 29946821
[TBL] [Abstract][Full Text] [Related]
3. Oxidative and nitrosative stress in myeloproliferative neoplasms: the impact on the AKT / mTOR signaling pathway.
Djikic D; Markovic D; Bogdanovic A; Mitrovic-Ajtic O; Suboticki T; Diklic M; Beleslin-Cokic B; Bjelica S; Kovacic M; P Cokic V
J BUON; 2018; 23(5):1481-1491. PubMed ID: 30570876
[TBL] [Abstract][Full Text] [Related]
4. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N; Guglielmelli P; Vannucchi AM
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
[TBL] [Abstract][Full Text] [Related]
5. Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms.
Keski H
Blood Cells Mol Dis; 2020 May; 82():102420. PubMed ID: 32179412
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm.
Wang JC; Kundra A; Andrei M; Baptiste S; Chen C; Wong C; Sindhu H
Leuk Res; 2016 Apr; 43():39-43. PubMed ID: 26943702
[TBL] [Abstract][Full Text] [Related]
7. pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.
Wiśniewska-Chudy E; Szylberg Ł; Dworacki G; Mizera-Nyczak E; Marszałek A
Oncol Rep; 2017 Apr; 37(4):2295-2307. PubMed ID: 28260027
[TBL] [Abstract][Full Text] [Related]
8. Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells.
Guglielmelli P; Bisognin A; Saccoman C; Mannarelli C; Coppe A; Vannucchi AM; Bortoluzzi S
PLoS One; 2015; 10(10):e0140445. PubMed ID: 26468945
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of myeloproliferative neoplasms.
Skoda RC; Duek A; Grisouard J
Exp Hematol; 2015 Aug; 43(8):599-608. PubMed ID: 26209551
[TBL] [Abstract][Full Text] [Related]
10. Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms.
Čokić VP; Mitrović-Ajtić O; Beleslin-Čokić BB; Marković D; Buač M; Diklić M; Kraguljac-Kurtović N; Damjanović S; Milenković P; Gotić M; Raj PK
Mediators Inflamm; 2015; 2015():453020. PubMed ID: 26491227
[TBL] [Abstract][Full Text] [Related]
11. The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
Kiem D; Wagner S; Magnes T; Egle A; Greil R; Melchardt T
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502471
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.
Patterson-Fortin J; Moliterno AR
Curr Hematol Malig Rep; 2017 Oct; 12(5):424-431. PubMed ID: 28948454
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
[TBL] [Abstract][Full Text] [Related]
14. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
[TBL] [Abstract][Full Text] [Related]
15. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
Benati M; Montagnana M; Danese E; De Matteis G; Veneri D; Paviati E; Guidi GC
Clin Chem Lab Med; 2015 Jun; 53(7):1005-11. PubMed ID: 25527813
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations.
Lekovic D; Gotic M; Skoda R; Beleslin-Cokic B; Milic N; Mitrovic-Ajtic O; Nienhold R; Sefer D; Suboticki T; Buac M; Markovic D; Diklic M; Cokic VP
Ann Hematol; 2017 Mar; 96(3):393-404. PubMed ID: 27924369
[TBL] [Abstract][Full Text] [Related]
17. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.
da Silva RR; Domingues Hatzlhofer BL; Machado CG; Lima AS; de Albuquerque DM; dos Santos MN; Fertrin KY; Costa FF; Araújo Ada S; Bezerra MA
Genet Test Mol Biomarkers; 2012 Jul; 16(7):802-5. PubMed ID: 22304488
[TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
19. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in myeloproliferative neoplasms: Causes and consequences.
O'Sullivan J; Mead AJ
Adv Biol Regul; 2019 Jan; 71():55-68. PubMed ID: 30528537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
